Daiichi Sankyo has increased focus on high growth oncology and entered into a potentially very lucrative deal with Merck. We like the company, we like the focus, but the valuation concerns us.
What is covered in the Full Insight:
Overview of Japan's Oncology Market
Transformation of Daiichi Sankyo
Focus on Oncology
Agreements and Partnerships
Earnings Outlook and Valuation
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.